Estimated sales for 2022 is disclosed in International Financial Reporting Standards (IFRS).
May 11. 2022
(¥ million)
| Brand name | Active Ingredient | Indications | Launch Date |
Sales 2020 (JGAAP) |
Sales 2021 (JGAAP) |
Sales 2022 (IFRS) (estimated) |
|
|---|---|---|---|---|---|---|---|
| Apr-Sep | Annual | ||||||
| Vidaza | azacitidine |
myelodysplastic syndrome/ acute myeloid leukemia |
Mar-2011/ Mar-2021 |
15,350 | 18,338 | 7,800 | 12,400 |
| Uptravi | selexipag |
pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension |
Nov-2016/ Aug-2021 |
6,804 | 8,400 | 4,500 | 9,800 |
| Viltepso | 2,387 | 7,750 | 5,900 | 13,000 | |||
| (Japan) | viltolarsen |
Duchenne muscular dystrophy |
Japan May-2020 U.S. Aug-2020 |
(1,953) | (4,059) | (2,200) | (4,750) |
| (U.S.) | (434) | (3,691) | (3,700) | (8,250) | |||
| Tramal, Onetram | tramadol hydrochloride | cancer pain, chronic pain | Sep-2010 | 6,906 | 6,770 | 2,700 | 5,000 |
| Gazyva | obinutuzumab | CD20-positive follicular lymphoma | Aug-2018 | 5,312 | 5,300 | 2,700 | 5,800 |
| Adcirca | tadalafil | pulmonary arterial hypertension | Dec-2009 | 5,474 | 4,563 | 1,400 | 2,500 |
| Zalutia | tadalafil | urinary disorder caused by benign prostatic hyperplasia | Apr-2014 | 6,743 | 4,106 | 1,300 | 2,300 |
| Cialis | tadalafil | erectile dysfunction | Jul-2009 | 2,677 | 2,532 | 1,250 | 2,600 |
| Erizas | dexamethasone cipecilate | allergic rhinitis | Dec-2009 | 2,444 | 2,330 | 700 | 2,400 |
| Defitelio | defibrotide sodium | sinusoidal obstruction syndrome | Sep-2019 | 1,970 | 2,128 | 1,000 | 2,300 |
| Profit in co-promotion | 8,442 | 8,934 | 4,600 | 9,500 | |||
| Revenues from the licensing of industrial property rights | 24,338 | 33,207 | 14,600 | 29,800 | |||
| Pharmaceuticals | 106,478 | 120,650 | 57,400 | 115,000 | |||
| Functional Food | 15,406 | 16,897 | 9,600 | 19,000 | |||
| Net Sales | 121,885 | 137,547 | 67,000 | 134,000 | |||
| Brand name | Active Ingredient | Indications | Launch Date |
Sales 2020 (JGAAP) |
Sales 2021 (JGAAP) |
Sales 2022 (IFRS) (estimated) |
|
|---|---|---|---|---|---|---|---|
| Apr-Sep | Annual | ||||||
| Vidaza | azacitidine |
myelodysplastic syndrome/ acute myeloid leukemia |
Mar-2011/ Mar-2021 |
15,350 | 18,338 | 7,800 | 12,400 |
| Uptravi | selexipag |
pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension |
Nov-2016/ Aug-2021 |
6,804 | 8,400 | 4,500 | 9,800 |
| Viltepso | 2,387 | 7,750 | 5,900 | 13,000 | |||
| (Japan) | viltolarsen |
Duchenne muscular dystrophy |
Japan May-2020 U.S. Aug-2020 |
(1,953) | (4,059) | (2,200) | (4,750) |
| (U.S.) | (434) | (3,691) | (3,700) | (8,250) | |||
| Tramal, Onetram | tramadol hydrochloride | cancer pain, chronic pain | Sep-2010 | 6,906 | 6,770 | 2,700 | 5,000 |
| Gazyva | obinutuzumab | CD20-positive follicular lymphoma | Aug-2018 | 5,312 | 5,300 | 2,700 | 5,800 |
| Adcirca | tadalafil | pulmonary arterial hypertension | Dec-2009 | 5,474 | 4,563 | 1,400 | 2,500 |
| Zalutia | tadalafil | urinary disorder caused by benign prostatic hyperplasia | Apr-2014 | 6,743 | 4,106 | 1,300 | 2,300 |
| Cialis | tadalafil | erectile dysfunction | Jul-2009 | 2,677 | 2,532 | 1,250 | 2,600 |
| Erizas | dexamethasone cipecilate | allergic rhinitis | Dec-2009 | 2,444 | 2,330 | 700 | 2,400 |
| Defitelio | defibrotide sodium | sinusoidal obstruction syndrome | Sep-2019 | 1,970 | 2,128 | 1,000 | 2,300 |
| Profit in co-promotion | 8,442 | 8,934 | 4,600 | 9,500 | |||
| Revenues from the licensing of industrial property rights | 24,338 | 33,207 | 14,600 | 29,800 | |||
| Pharmaceuticals | 106,478 | 120,650 | 57,400 | 115,000 | |||
| Functional Food | 15,406 | 16,897 | 9,600 | 19,000 | |||
| Net Sales | 121,885 | 137,547 | 67,000 | 134,000 | |||